Quick Answer
Arbutus Biopharma Corp reported Total Revenue of $14.08 million for fiscal year 2025.
Arbutus Biopharma Corp Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $14.08M | +128.2% |
| 2024 | $6.17M | -66.0% |
| 2023 | $18.14M | -53.5% |
| 2022 | $39.02M | +255.1% |
| 2021 | $10.99M | +58.9% |
| 2020 | $6.91M | +15.0% |
| 2019 | $6.01M | +1.1% |
| 2018 | $5.95M | -44.4% |
| 2017 | $10.70M | +617.6% |
| 2016 | $1.49M | -93.6% |
| 2015 | $23.28M | +55.7% |
| 2014 | $14.95M | -3.3% |
| 2013 | $15.46M | +9.6% |
| 2012 | $14.11M | -16.1% |
| 2011 | $16.81M | -21.3% |
| 2010 | $21.35M | +48.0% |
| 2009 | $14.43M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $529.0K | -60.5% | -95.1% |
| June 30, 2025 | $10.74M | +522.2% | +508.8% |
| March 31, 2025 | $1.76M | +15.1% | +31.7% |
| September 30, 2024 | $1.34M | -71.3% | -22.4% |
| June 30, 2024 | $1.73M | -62.9% | +12.7% |
| March 31, 2024 | $1.53M | -77.1% | -67.1% |
| September 30, 2023 | $4.66M | -21.7% | +0.2% |
| June 30, 2023 | $4.65M | -67.3% | -30.4% |
- Arbutus Biopharma Corp showed an increase of +128.2% in Total Revenue compared to the prior fiscal year.
- Over the 2009–2025 period, Arbutus Biopharma Corp’s total revenue has declined by 2.4% (from $14.43 million to $14.08 million).
- The most recent figure is from Arbutus Biopharma Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: